A Biotech Play “On The Right Side Of Volatility”
When it comes to stock selection, avoiding losers is just as important – and maybe even more important – than picking winners. This is why… Read More »A Biotech Play “On The Right Side Of Volatility”
Investing and Market Analysis
Is The Sell-Off In This Biotech Stock A Buying Opportunity? Cathie Wood Thinks So.
In the wake of the company disclosing in May that it would be delaying its Biologic License Application filing with the FDA for its key… Read More »Is The Sell-Off In This Biotech Stock A Buying Opportunity? Cathie Wood Thinks So.
Selecting The Best Biotech Penny Stocks
Even as many big names in biotech perform well, the author of today’s article notes that “penny biotech stocks, mostly small firms working on only… Read More »Selecting The Best Biotech Penny Stocks
Should Investors “Say Yes To Drugs” On Heels Of Biogen Approval?
The FDA’s approval of Biogen’s Alzheimer’s drug Aduhelm resulted in shares of the biotech rocketing higher – and the rest of the biotech sector went… Read More »Should Investors “Say Yes To Drugs” On Heels Of Biogen Approval?
A Promising Drug Candidate For Both Alzheimer’s And Parkinson’s Disease Could Drive This Surging Biotech Even Higher
The biotech featured in today’s article, focused on a new scientific approach to tackling Alzheimer’s disease and other neurodegenerative disorders, is up 884% so far… Read More »A Promising Drug Candidate For Both Alzheimer’s And Parkinson’s Disease Could Drive This Surging Biotech Even Higher
Potential June Catalysts Make These 4 Biotech Penny Stocks To Watch
What makes the four biotech penny stocks highlighted in today’s article ones to watch this month? They are all releasing key information which could serve… Read More »Potential June Catalysts Make These 4 Biotech Penny Stocks To Watch
Filling In The Missing Parts Of The Genetic Map Could Translate Into Huge Gains For This Biotech
While the Human Genome Project was declared complete 20 years ago, the mapping of the human genome was not truly complete. As the author of… Read More »Filling In The Missing Parts Of The Genetic Map Could Translate Into Huge Gains For This Biotech
Reading The Tea Leaves On Some Major Biotech Catalysts This Month
This month in biotech, “Some of the industry’s biggest players are waiting for clinical trial results and decisions from the FDA that could send their… Read More »Reading The Tea Leaves On Some Major Biotech Catalysts This Month
A Moment Of Truth For Biogen’s Alzheimer’s Drug – And The Biotech Sector
As the deadline for the FDA to decide whether to approve it nears, Biogen’s much-debated Alzheimer’s drug aducanumab faces its moment of truth – and… Read More »A Moment Of Truth For Biogen’s Alzheimer’s Drug – And The Biotech Sector
These 3 Pharmaceutical Stocks Look Significantly Undervalued
After being the target of much investor attention amid the COVID-19 pandemic, many investors have rotated out of the pricey pharmaceutical sector over the past… Read More »These 3 Pharmaceutical Stocks Look Significantly Undervalued